Share Now
Comparison of Shield Plan Non Cancer Drug List Coverage 2023

Shield Plan Non-Cancer Drug List Coverage (Comparison)

Greetings, readers in Singapore! Today, we are embarking on a journey to delve into the world of non-cancer drug list (non-CDL) coverage provided by various Shield Plans. Whether you are contemplating a switch to a new plan or simply seeking information on available options, this article will offer a comprehensive comparison of non-cancer drug list coverage within different Shield Plans. So, let’s kick things off!

Navigating Transformations in Shield Plans (IPs) and MSHL Coverage

Are you well-acquainted with Integrated Shield Plans (IPs)? They have gained significant popularity because they extend coverage beyond the fundamental MediShield Life (MSHL) plan provided by the government. IPs encompass a broad spectrum of hospitalization expenses, including inpatient treatments, day surgeries, and select outpatient treatments.

Revised MSHL Coverage

Starting from September 1, 2022, MSHL will limit its coverage to treatments listed in the Cancer Drug List (CDL). This change has been prompted by the escalating costs of non-CDL treatments, which, in turn, have led to higher premiums for both IPs and MSHL.

Summary of MSHL, MSV and IP (Private Insurer component) Changes
Source: MOH

Alterations in Outpatient Cancer Treatment Benefits

The policy regarding outpatient cancer treatment benefits has undergone noteworthy changes that warrant your attention. Commencing on April 1, 2023, two fresh benefits will replace the former policy. These new benefits comprise the Cancer Drug Treatment benefit and the Cancer Drug Services benefit. Here is what you need to know:

  • Cancer Drug Treatment Benefit: This allows you to claim expenses related to cancer drug treatments listed on the CDL, up to a specific limit. For treatments not listed on the CDL, you can make claims by availing suitable riders.
  • Cancer Drug Services Benefit: This covers various services linked to your outpatient cancer drug treatment, encompassing treatments not listed on the CDL, such as consultations, scans, lab investigations, treatment preparation and administration, supportive care drugs, and blood transfusions. Claims under this benefit are permitted up to specified claim limits.

Impact of CDL on Your Shield Plan (IP) Coverage

Understanding the CDL Impact on Your IP Coverage

For most IPs, this modification will take effect on 1st April 2023. Treatments that are not precisely in accordance with the CDL specifications will be non-claimable.

Exploring the Need for IP Riders

This implies that if you require coverage for non-CDL treatments, it becomes necessary to secure an IP rider. An IP rider serves as an additional insurance policy offering expanded coverage for treatments not included in MSHL or the basic IP plans.

Diverse IP Rider Options

Various insurers offer a selection of IP rider options, each with its unique features. These include Enhanced IncomeShield with riders, Singlife Shield with riders, GE SupremeHealth with rider, Prushield with rider, AIA Healthshield Goldmax with rider, Raffles Shield with riders, and HSBC Life Shield with Enhanced Care Rider. These plans come with varying annual limits, ranging from $30,000 to $360,000 per year, along with diverse co-payment percentages.

Comparing IP Rider Coverage: Shield Plan Non Cancer Drug List Coverage

Here are some insurers’ IP rider coverage options for non-CDL treatments that can give you an idea of what to expect:

1) Enhanced IncomeShield with Riders: Non Cancer Drug List Coverage

  • Enhanced IncomeShield, a prominent IP provider in Singapore, offers a generous annual limit of $1,500,000.
  • They feature two distinct shield plan riders for non-cancer drug list coverage, namely Classic Care and Deluxe Care, both boasting a monthly benefit limit of $15,000 ($180,000 per year) without a co-payment cap. However, the co-payment percentage differs between the two riders: Deluxe Care entails a 10% co-payment, while Classic Care has a 20% co-payment.

2) Singlife Shield with Health Plus Rider: Non Cancer Drug List Coverage

  • Singlife Shield, formerly known as Aviva MyShield, is another distinguished IP provider. Their basic plan offers a substantial $2,000,000 policy year limit.
  • If you require extra coverage for non-CDL treatments, an IP rider is available, granting $30,000 per year in coverage with a 5% co-payment.

3) GE SupremeHealth with TotalCare Rider: Non Cancer Drug List Coverage

  • GE SupremeHealth, a well-established IP provider in Singapore, features a generous annual limit of $1,500,000.
  • They also offer an IP rider for additional non-CDL coverage, providing $250,000 per year in coverage with a 5% co-payment.

4) Prushield with PRUExtraRider: Non Cancer Drug List Coverage

  • Prushield, another reputable IP provider in Singapore, offers a commendable basic plan with an annual limit of $1,200,000.
  • Similar to other insurers, they present IP riders for non-CDL treatments. If you require additional coverage for non-CDL treatments, you can acquire an IP rider that extends $150,000 per year in coverage with a 5% co-payment.

5) AIA Healthshield Gold Max with Max VitalHealth Rider + Max A Cancer Care Booster: Non Cancer Drug List Coverage

  • AIA Healthshield Gold Max offers a generous yearly benefit limit of $2,000,000.
  • Like other insurers, they also provide IP riders for non-CDL treatments. If needed, you have the option to acquire shield plan riders for supplementary coverage, providing $200,000 per year in coverage with a 5% co-payment.

6) Raffles Shield with Key Rides + Raffles Cancer Guard Rider: Non Cancer Drug List Coverage

  • Raffles Shield, a newer entrant in the IP market, offers a basic plan with a substantial annual limit of $1,500,000.
  • They furnish several shield plan riders for additional coverage concerning the non-cancer drug list, including Key Rider/Premier Rider and Raffles Cancer Guard Rider, both extending $250,000 per year in coverage with a 5% co-payment.

7) HSBC Life Shield with Enhanced Care Rider: Non Cancer Drug List

  • HSBC Life Shield, the latest IP provider in Singapore, offers a basic plan with a high annual limit of $2,500,000.
  • They also present an Enhanced Care Rider for supplementary coverage related to the non-cancer drug list. If needed, this rider provides a monthly benefit limit of $30,000 (~$360,000 per year Highest in market) with a 5% co-payment.

Shield Plan Rider Options for Non-CDL Treatments

Comparison of Shield Plan Non Cancer Drug List Coverage 2023

Important Considerations for Non Cancer Drug List Coverage of Various Shield Plans

Evaluating Your Integrated Shield Plan

When selecting an Integrated Shield Plan, it’s crucial to scrutinize the coverage for non-cancer drugs list. Keep in mind that different insurers have varying limits on outpatient non-CDL treatments, so it’s advisable to consult your insurer to comprehend their coverage and constraints.

Stay Informed for Enlightened Choices

While you can typically find this information on your insurer’s website, it’s essential to note that the details may change due to the dynamic nature of Integrated Shield Plans and MediShield Life coverage. Stay informed to make the best decisions for yourself and your loved ones!

Understanding Your Cancer Insurance Options in Singapore

Shield Plan Non-Cancer Drug List Coverage (Comparison)

Singapore’s healthcare system has experienced significant transformations in recent years. Staying well-informed about your insurance coverage is vital to ensure that it aligns with your current healthcare needs and financial capabilities.

Government Initiatives for Cancer Patients

Although these changes may seem complex, they aim to ensure that every Singaporean has access to crucial healthcare treatments, particularly for cancer. The government acknowledges that cancer treatment can be financially demanding. They have increased coverage for cancer treatments under MediShield Life and MediSave, allowing cancer patients to access more advanced and effective treatments at reduced costs, encompassing targeted and immunotherapy treatments.

The Role of IP Riders

However, not all cancer treatments are covered under the Cancer Drug List. This is where IP riders come into play. IP riders offer supplementary coverage for Non-CDL Treatment, which includes cancer treatments not listed in the Cancer Drug List, such as surgery, radiotherapy, and chemotherapy.

Exploring Your Cancer Insurance Options

In Singapore, there are several options available for covering the costs associated with cancer treatment. These options include:

  1. Critical Illness Insurance: This type of insurance provides a lump-sum payout upon the diagnosis of a critical illness, including cancer. The payout can be used to cover treatment costs, lost income, or other expenses incurred during the treatment.
  2. Cancer Insurance: Some insurance companies offer standalone cancer insurance policies designed specifically to cover cancer-related expenses, such as hospitalization, surgery, chemotherapy, and radiation therapy.
  3. Employer-provided Health Insurance: Some employers provide health insurance coverage that includes cancer treatment. Be sure to check with your employer to determine if such coverage is offered.

Choosing the Right Plan

When selecting a cancer insurance plan, carefully review the policy’s terms, including coverage limits, waiting periods, and exclusions. Compare premiums and benefits across plans to identify the best option that aligns with your specific needs and budget.

Budget and Coverage Considerations

IP rider costs can vary, so it’s important to choose one that fits within your budget while ensuring adequate coverage. Prior to making a decision, thoroughly review the insurer’s limits and co-payment percentages.

Conclusion: Staying Informed and Prepared

Despite the initial complexity, the changes in healthcare insurance coverage have been implemented to make sure that everyone in Singapore can access crucial healthcare treatments, especially for cancer. To ensure your insurance aligns with your healthcare needs and budget, stay informed and periodically reevaluate it.

Takeaway: Important Changes to Integrated Shield Plan (IPs) Coverage Starting April 1, 2023

Key Changes Affecting Your IP Coverage

Learn about the important changes to Integrated Shield Plan (ISP) coverage affecting your cancer insurance options in Singapore.

To wrap things up, the Integrated Shield Plan (IPs) has undergone major changes that will impact your coverage. This means that most basic IP plan will now only cover treatments listed under the Cancer Drug List. So if you need Non-CDL Treatment, you might want to consider getting an IP rider.

Regular Review for Ongoing Relevance

Remember, it’s important to regularly review your insurance coverage to make sure it fits your healthcare needs and budget.

Got Questions or Concerns? We’re Here to Help

If you have any questions or concerns, feel free to reach out to us for more information. We’re here to help you navigate the changes and make the best decisions for your health and well-being!

Comments are closed.

  • MoneyLine.sg is an independent information provider. It is not a bank or financial services provider and cannot give direct financial advice.
  • All Sample Premium results if shown are based on the criteria indicated and MoneyLine.sg does not warrant or guarantee that anything written here is accurate, timely, or relevant to the solution of any problem you may have.
  • Contents are intended as general information only and do not consider financial situation or need of any user or reader, any specific person or group of persons. It does not constitute advice nor does any part of the content constitute an open offer capable of forming the basis of a contract.
  • Moneyline.sg works with Synergy Financial Advisers to present these contents. Synergy Financial Advisers makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose. All information provided is not intended to be and does not constitute financial advice, insurance advice or any other advice or recommendation of any sort offered or endorsed by Synergy Financial Advisers.
  • Promotions indicated on this page may not be accurate and may be subjected to changes by providers without warning. Moneyline.SG does not take responsibility for the accuracy of the information shown in this content.
  • You are recommended to seek financial advice from a qualified financial advisor for product suitability and its latest premium rates quotation before deciding to purchase the product. In the event you choose not to seek advice, you should consider if the product is suitable for you.
  • Without prejudice to the generality of this, MoneyLine.sg Pte Ltd specifically excludes liability for any loss or damage no matter how arising from the use of this Web Portal or of any information or services provided through this web portal.
  • Please read our full Disclaimer on the use of our website.